Open AccessSuccessful ruxolitinib administration for a patient with steroid‐refractory idiopathic pneumonia syndrome following hematopoietic stem cell transplantation: A case report and literature review
Author(s) -
Tomomasa Dan,
Isoda Takeshi,
Mitsuiki Noriko,
Yamashita Motoi,
Morishita Aoi,
Tomoda Takahiro,
Okano Tsubasa,
Endo Akifumi,
Kamiya Takahiro,
Yanagimachi Masakatsu,
Imai Kohsuke,
Kanegane Hirokazu,
Takagi Masatoshi,
Morio Tomohiro
Publication year - 2021
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.5242
Subject(s) - medicine , ruxolitinib , hematopoietic stem cell transplantation , pneumonia , adverse effect , stem cell , cryptogenic organizing pneumonia , transplantation , complication , refractory (planetary science) , lung , intensive care medicine , bone marrow , physics , biology , astrobiology , myelofibrosis , genetics
Idiopathic pneumonia syndrome (IPS) is an acute lung complication observed after the early posthematopoietic stem cell transplantation (HSCT) period. Ruxolitinib was effective for a patient with myelodysplastic syndrome who developed severe IPS after second HSCT. No severe adverse effects were observed. Ruxolitinib may be an alternative choice for HSCT‐related IPS.